MiMedx Group, Inc

MDXG Healthcare Biotechnology

MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024.

Revenue
−45.2%
EPS
−154.1%
Free cash flow
−87.2%
Total debt
−6.80%

Quarter to September 2026, against a year earlier

3.31 0.03 +0.91%
Market cap
$478.6M
P/E
0.0×
Fwd P/E
−14.9×
Dividend yield
—
F-score
5/9
Altman Z
9.38
Beneish M
−2.68
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

5 5 5 4
ROE
21.61% 13.77% 2.88% (8.53%)
ROA
16.02% 10.60% 2.18% (6.58%)
ROIC
36.84% 24.56% 5.62% (17.40%)
Return on Tangible Assets
22.29% 15.31% 3.63% (12.89%)
Average Days of Receivables
66.01 43.15 42.44 44.79
Free Cash Flow per Share
0.49 0.47 0.30 0.13
Free Cash Flow
72.97 69.31 44.43 19.02
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026